Contents

SCORE2: Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion

May, 2017

Clinical trial

Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.

Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J.

JAMA. 2017 May 23;317(20):2072-2087.
Full text | Metrics.

Main finding: Intravitreal Bevacizumab was non-inferior to Aflibercept in 6-month visual outcomes in macular oedema secondary to central/hemi-RVO

 

  • Purpose: To investigate whether bevacizumab is noninferior to aflibercept for the treatment of macular edema secondary to central retinal or hemiretinal vein occlusion
  • Study type: Randomized controlled trial.
  • Condition: Central/hemi- retinal vein occlusion

Participants: ≥18 yo with macular oedema secondary to C/Hemi-RVO, ETDRS VA score 19-73, mean central subfield thickness ≥300-320 μm

 

  • n=362

 

Intervention:

 

Group 1: Intravitreal Bevacizumab 1.25mg q4weekly
Group 2: Intravitreal Aflibercept 2mg q4weekly

Mean VA letter score improvement was similar between both groups (18.6 vs 18.9); Bevacizumab was non-inferior to Aflibercept.

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed